Related Experiment Video
Updated: Aug 15, 2026

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
Published on: September 14, 2014
What's new in HIV/AIDS? Neutralizing HIV antibodies: do they really protect?
1Dept. of Infectious Diseases, Medical Policlinic, Ludwig Maximilian University Munich, Pettenkoferstr. 8a, 80336 Munich, Germany. Frank.Goebel@med.uni-muenchen.de
Abstract:
Neutralizing antibodies work as a second line of defence. They are detected more or less in nearly every HIV-1-infected individual. 2G12, 2F5 and 4E10 represent antibodies with broadly neutralizing activity made from B cells of HIV- 1-infected humans. Unfortunately these antibodies are extremely rare and all attempts to elicit them via vaccine immunogens have failed. The discovery of autoreactive features of these antibodies could now explain why. Additionally, new results show the delayed viral rebound under antibody treatment in some HIV-1-infected individuals.
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Retrovirus Life Cycles
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Cross-reactivity

